Regulatory Framework and Therapeutic Context

In Australia, nicotine-containing vaping products are classified by the Therapeutic Goods Administration (TGA) as therapeutic goods and regulated accordingly. Their supply is restricted to pharmacies and authorised healthcare settings, in line with relevant scheduling, quality, and labelling requirements.

These products are intended for use under professional supervision as part of a clinically guided smoking cessation strategy, supporting eligible adult patients to managing nicotine dependence and transition away from combustible tobacco. They are not supplied or promoted for recreational use.

BayPharma develops and supplies therapeutic nicotine vaping products that fully comply with all applicable Australian regulatory standards. These products are available through approved therapeutic supply pathways.

Product and System Types

Bay Pharma products include both closed or open delivery systems for the administration of nicotine. These systems allow for consistent delivery under controlled conditions and may support patients engaged in cessation programs.

Nicotine-free formulations are also available through the same regulated supply pathway. These are intended for patients who have reduced or discontinued nicotine use but continue to participate in a structured smoking cessation plan.

All products, whether containing nicotine or not, are subject to the same manufacturing and distribution standards required for therapeutic goods. It is important for pharmacies to source compliant products that meet the Australian regulatory standards for therapeutic goods.